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Neurodegenerative diseases constitute a heterogeneous group of age-related disorders
that are characterized by a slow but irreversible deterioration of brain functions. Evidence
accumulated over more than two decades has implicated calcium-related homeostatic
mechanisms, giving rise to the Ca2+ hypothesis of brain aging and, ultimately, cell
death. Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter within
the central (CNS), peripheral and enteric nervous systems. It appears to be involved in
a wide variety of physiological functions within and outside the nervous system, that
are maintained through a complex interaction between GABA and calcium-dependent
neurotransmission and cellular metabolic functions. Within CNS the Ca2+/GABA
mechanism stabilizes neuronal activity both at cellular and systemic levels. Decline
in the Ca2+/GABA control initiates several cascading processes leading to both
weakened protective barriers (in particular the blood-brain barrier) and accumulations
of intracellular deposits of calcium and Lewy bodies. Linking such a vital mechanism of
synaptic transmission with metabolism (both at cellular and tissue level) by means of a
common reciprocal Ca2+/GABA inhibition results in a fragile balance, which is prone to
destabilization and auto-destruction. The GABA decline etiology proposed here appears
to apply to all human neurodegenerative processes initiated by abnormal intracellular
calcium levels. Therefore, the original description of Parkinson’s disease (PD) as due to
the selective damage of dopaminergic neurons in the mesencephalon should be updated
into the concept of a severe multisystemic neurodegenerative disorder of the nervous
system, whose clinical symptoms reflect the localization and progression of the most
advanced GABA pathology. A future and more complete therapeutic approach to PD
should be aimed first at slowing (or stopping) the progression of Ca2+/GABA functional
decline.
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CURRENT VIEWS ON THE ETIOLOGY OF PARKINSON’S DISEASE
Neurodegenerative diseases constitute a heterogeneous group of disorders of the nervous system
that are characterized by a slow but irreversible deterioration of brain functions. These diseases have
devastating effects on patients and are often accompanied by tremendous physical and emotional
burden not only for the patients but also for their families and friends. Parkinson’s disease (PD)
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is progressive and the second most common neurodegenerative
disorder (Brooks, 1998; Bergman and Deuschl, 2002). For
decades, the clinical diagnosis of PD was based on a set
of motor symptoms such as: rigidity, bradykinesia, akinesia,
abnormal posture and resting tremor (Błaszczyk, 1998; Brooks,
1998; Bergman and Deuschl, 2002; Siderowf and Lang, 2012).
The motor symptoms of PD have been linked with a loss
of dopamine neurons in the substantia nigra pars compacta
(SNPC) and a consequential reduction in the level of dopamine
input in the striatum. These served as the neurophysiological
hallmarks for diagnosis, although at least a 50–70% decrease in
the nigrostriatal dopaminergic system occurs before the onset of
clinical parkinsonism (Błaszczyk, 1998; Brooks, 1998; Bergman
and Deuschl, 2002; Siderowf and Lang, 2012). Such significant
brain lesion does not permit any effective medical treatment. To
date, the therapy of PD is symptomatic, aimed at ameliorating
motor symptoms.
Primary PD is referred to as idiopathic and understanding
its causes has been an inspiration for many studies. Evidence
accumulated over more than two decades has implicated
calcium-related homeostatic mechanisms, giving rise to the Ca2+
hypothesis of brain aging and, ultimately, cell death (Disterhoft
et al., 1996; Jagmag et al., 2016). Recently, the oxidative
stress and calcium-induced excitotoxicity were considered
important pathomechanisms leading to neural cell death in
PD. Unfortunately, factors that make some neurons vulnerable
to neurodegeneration while others remain resistant were not
identified until now.
For biochemists, the formation of intracellular deposits of
proteins and lipids that precede neuronal death seemed to
be the most likely factor. The Lewy bodies, with deposits of
alpha-synuclein (α-SNCA), turned out to be expressed robustly
TABLE 1 | Main brain structures that are affected at different stages of the Parkinson’s disease: symptoms and causes of their neurodegeneration.
PD Phase Brain structures affected Symptoms Main cause of deficit
Prodromal
(Braak Stage 1 and 2)
Olfactory bulbs and olfactory nuclei Hyposmia or anosmia (not responsive
to antiparkinsonian drugs)
Damage of the dopaminergic neurons. Role
of GABA undetermined yet.
Dorsal nucleus of the vagus nerve Dysautonomia, gastrointestinal
disturbances, constipation
Ca2+/GABA
Nucleus ambiguus Glossopharyngeal control deficit Ca2+/GABA
Locus coeruleus and hypothalamus
(orexin)
Sleep disturbance, anxiety Progressing deficiency of the noradrenergic,
serotonergic and dopaminergic systems due
to GABA deficit
Mesolimbic DA system nigrostriatal DA
system
Depression, anhedonia, anxiety,
impaired movement motivation,
hypomimia
GABA deficiency and neurodegeneration of
DA neurons, and glial-based synaptic
dysfunction
Clinical
(Braak Stage 3 and 4)
Striato-pallidal complex (input) Bradykinesia, akinesia Increased threshold of GABA medium spiny
neurons
Striato-pallidal complex (output) Stiffness, tremor, bradykinesia,
postural instability
Decreased spontaneous GABA activity
(decline in GABA inhibition of competitive
motor programs)
Late
(Braak stage 5 and 6)
Striato-hippocampal complex Cognitive and memory alterations Ca2+/GABA induced neurodegeneration
Thalamocortical system (prefrontal,
motor, sensory, and cingular cortices)
Motivational, cognitive, sensory, and
motor deficiencies
Ca2+/GABA-interaction collapse and
generalized neurodegeneration
in neurodegenerating structures (Moore et al., 2005; Cookson,
2009; Beach et al., 2010). Pathological inclusions are thought
to form in a small number of cells and-given enough time
and, perhaps, a genetic predisposition-spread in a deterministic
manner to distant brain regions (Braak et al., 2003, 2004;
Goedert, 2015). Since α-SNCA deposition occurs early in PD, its
immunohistochemistry has become the current gold standard in
the neuropathological evaluation of PD.
The distribution of Lewy pathology in PD brains seems
to be limited to specific brain regions and neuronal types,
and develops in a structured, temporal pattern (Braak et al.,
2004). The mechanisms underlying PD are believed to be
cell-autonomous which implies that the same physiological or
molecular events, such as the formation α-SNCA assemblies,
occur independently in a large number of cells in an otherwise
healthy brain. According to Braak’s six-stage scheme (Table 1),
the pathology begins (stages 1 and 2) when neurodegeneration
and Lewy bodies are confined to the olfactory system, dorsal
motor nucleus of the glossopharyngeal and vagal nerves, locus
coeruleus, and reticular formation. Then, in stages 3 and 4,
the neuropathological damage extends to the SNPC, other
mesencephalic nuclei, the prosencephalon and mesoallocortical
regions. During these stages, the motor symptoms develop
and progressively worsen. The pathology gradually follows an
ascending course, culminating in widespread synucleinopathy
(stages 5 and 6), involving neocortical, prefrontal, and associative
cortices. Consequently, in the advanced stages, severe motor
disturbances are accompanied by cognitive and behavioral
symptoms.
There are, however, several weaknesses in the Braak model.
It does not explain the absence of clinical symptoms in subjects
with widespread synucleinopathy or accumulation of α-SNCA
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in specific brain areas only. Moreover, the Lewy pathology
has been identified in several neuronal populations other than
the dopaminergic mesencephalic ones (Braak et al., 2004;
Stefanis, 2012). Doubts can also be raised about the hypothesis
of the proposed “gut to brain” spread of Lewy pathology,
which claims that the pathology can initiate in the periphery,
gaining access to the central nervous system through retrograde
transport along projection neurons from the gastrointestinal
tract (Goedert, 2015; McCann et al., 2016). It seems rather that
the synucleinopathy may develop secondarily to intracellular
calcium accumulation and thus does not fully explain the
neurodegenerative processes.
Recently, the “triple hit” hypothesis has been advanced
(Mosharov et al., 2009). This hypothesis assumes that too
much calcium, plus a build-up of α-SNCA and increased
dopamine within the cells, may trigger neuronal death in
PD. Experimental observations confirmed that an increase
in calcium concentration inside neurons when accompanied
by intracellular accumulation of misfolded proteins, initiate
apoptosis when a certain physiological threshold is crossed. The
process of programmed cell death may be also accelerated by
excitotoxicity due to excessive neurotransmitter (or medication)
level (Mosharov et al., 2009).
The triple-hit model systematizes the views on
neurodegeneration and on PD, although the fundamental
problem of what causes the “triple hit” remains an open
question. To answer this question, one has to elucidate: (i)
what is the cause and mechanism of intracellular calcium
accumulation, and (ii) why only certain neural structures
are more prone to neurodegeneration, whilst in others, these
processes are less abrupt.
GABA AND PD PRODROMAL SYMPTOMS
Generally, patients with early PD have non-motor symptoms
such as a decreased sense of smell, depression, and various
gastrointestinal and other systemic features, which have been
shown to predate the classical motor features of PD (Pellicano
et al., 2007; Stefanis, 2012), and which are undoubtedly related to
the deficit of GABA. These pre-motor signs and symptoms could
be used to screen for PD before it reaches symptomatic Braak
stage 3 (for details see Table 1).
Research results gathered to date, point to very interesting
facts. Firstly, the cell types in the central nervous system
exhibiting a propensity for developing Lewy pathology share
several common features; neurons with long, thin, unmyelinated
or poorly myelinated axons are particularly susceptible to
develop lesions (Cookson, 2009; Hurley et al., 2013). Secondly,
Parkinson’s disease in its early stages extends far beyond the
boundaries of the CNS, affecting the peripheral and enteric
nervous systems. For this reason, a wide range of prodromal
non-motor symptoms, related to various neural dysfunctions
are observed in early PD. In preclinical symptoms, there is no
absolute selectivity for any specific neurotransmitter group or
brain area (Cookson, 2009). For instance, the pathophysiology of
dysautonomia in PD includes the degeneration and dysfunction
of autonomic nuclei such as the dorsal vagal nucleus, the nucleus
ambiguus, and other medullary nuclei, which exert differential
control on the sympathetic preganglionic neurons via descending
pathways (Pellicano et al., 2007).
It is intriguing that approximately 80% of newly diagnosed
PD patients have abnormal olfaction. The olfactory dysfunctions
in PD seem to depend on damage of the dopaminergic neurons
in the olfactory bulbs and olfactory nuclei and thus it can be a
prodromal marker of the disease (Stefanis, 2012). It is intriguing
that glia cell-derived neutrophic factor (GDNF) that is expressed
during neuro-glial interactions (and which is controlled by the
Ca2+/GABA mechanisms) may enhance survival and function
of the dopaminergic neurons both, in the midbrain and in the
olfactory system. From results of studies performed to date,
it appears that GDNF may function as a chemo-attractant for
GABAergic cells. GDNF is also a strong chemo-attractant for
axons of dopaminergic neurons. Its ectopic application results
in growth of the reinervating axons. Finally, another intriguing
therapeutic aspect of the GDNF expression is the possibility
of being regulated by physical activity (Ibáñez and Andressoo,
2016). Moreover, Vitamin D which is responsible for calcium
metabolism is also a potent inducer of endogenous GDNF
(Eserian, 2013).
During the premotor stages of PD other symptoms may
play a role as prodromal markers of the disease (Pellicano
et al., 2007). Depression and anxiety can be considered a non-
motor sign of PD, potentially useful in the early diagnosis of
PD. Depression is extremely frequent in PD, occurring in up
to 45% of cases. Also panic attacks, phobias, or generalized
anxiety disorder are frequently observed in PD patients. The
pathophysiology of depression in PD is rather complex, being
related to neurodegeneration of the noradrenergic, serotonergic
and dopaminergic pathways in the brain (Pellicano et al.,
2007). Recent studies indicate a possible diagnostic value of
plasma GDNF levels in depression, but whether GDNF and
related Ca2+/GABAmechanisms may play prominent role in the
development and progression of PD-related depression is unclear
at the moment (Ibáñez and Andressoo, 2016).
Intraneuronal ion equilibrium, including the optimal
calcium level, can be fully recovered during sleep (Siegel,
2009). Therefore, sleep deficit may increase neurodegeneration.
Virtually all PD patients develop sleep disruption, and there is
evidence that the process usually begins early in the course of the
disease. Sleep disturbance in PD has a multifactorial etiology, but
pathological degeneration of central sleep regulation centers in
the brainstem and thalamocortical pathways is probably the most
relevant factor (Stefanis, 2012). Mechanisms of sleep are very
complex, but the GABA system is involved in every its aspect
(Siegel, 2009). For instance, preoptic neurons and, the nucleus
reticularis, which forms a shell surrounding the thalamus,
contains GABAergic neurons known from low-threshold
calcium spikes (Siegel, 2009).
GABA-CALCIUM INTERACTION
The most relevant fact is that all brain structures (and, in
particular, those included in the Braak’s model), although
anatomically and physiologically diverse (e.g., using different
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combinations of neurotransmitters), share a common
mechanism that controls their activity and metabolism.
The control is just maintained through a complex interaction
between gama-aminobutyric acid and calcium-dependent
neurotransmission and calcium-dependent neuronal
metabolism.
The Ca2+/GABA mechanism stabilizes neuronal activity both
at the cellular and systemic levels. This close interaction, in
addition to the well-documented role of Ca2+ in brain aging and
neurodegeneration, allows one to hypothesize that a collapse of
the GABA system may be decisive in the initiation and running
of these processes. To validate the hypothesis one needs firstly, to
investigate GABA-dependent control, and secondly, to show the
symptoms and signs of its decline. In the latter case, the similarity
in the symptoms of GABA deficiency compared with those of PD
should be conclusive.
GABA is the main inhibitory neurotransmitter within the
central, peripheral and enterinal nervous systems (Vaucher et al.,
2000; Petroff, 2002; Watanabe et al., 2002). GABA appears to
be involved in a wide variety of physiological functions in
tissues outside the nervous system, including blood vessels,
skeletal muscles, gastrointenstinal tract, pituitary, thyroid,
adrenal gland, and thymus (Watanabe et al., 2002). Therefore,
a deficit of GABA results in chronic dysfunctions in many
systems.
Synaptic transmission is the primary mechanism in the
physiology of the nervous system including signal transmission,
adaptive adjustments, and memory. This mechanism utilizes the
Ca2+/GABA interaction to improve the efficiency of the signal-
to-noise ratio (Petroff, 2002; Yamakage and Namiki, 2002) and to
adjust the relatively fast electrical neuronal activity to the slower
biochemical andmetabolic processes. Within neuronal networks,
each action potential reaching presynaptic terminals opens
voltage-dependent calcium channels causing an influx of Ca2+
into cells. The “calcium token” acts as an intracellular messenger.
It controls both the trans-synaptic signal transmission and,
simultaneously, when reaching the mitochondria, the calcium
adjusts the cellular metabolism to activity-dependent demand
(Vaucher et al., 2000; Hawkins and Davis, 2005). In this
mechanism, the α-SNCA plays an important role in maintaining
a supply and release of synaptic vesicles in presynaptic terminals
in response to neuronal action potential (Berridge, 1998). In
addition, mitochondrial metabolic functions depend also on the
α-SNCA. Unfortunately, an excessive intracellular concentration
of calcium in combination with extravagant SNCA accumulation
leads to apoptosis and neurodegeneration (Mosharov et al.,
2009).
DEFICIT OF GABA AND
NEURODEGENERATION
To protect the neurons, the GABA system must precisely
control the calcium influx directly via GABAergic receptors
and, indirectly, via astrocytes and glial networks (Yamakage
and Namiki, 2002; Allaman et al., 2011). Activation of the
classical presynaptic receptors GABAA and GABAB results in a
hyperpolarization of neurons and plays a critical role in the long-
term inhibition of synaptic transmission (Watanabe et al., 2002;
Yamakage and Namiki, 2002). During the hyperpolarizing phase,
the voltage-gated calcium channels are blocked, thus protecting
neurons from Ca2+ toxicity and gives them time to remove the
surplus calcium ions (Mosharov et al., 2009; Hurley et al., 2013).
Removal of the divalent calcium ions from the mitochondria
and cytoplasm requires, however, significant amounts of energy
(and time), and therefore, calcium overloaded neurons have
high energy requirements (Surmeier and Schumacker, 2013).
Hence, much evidence suggests a major role of mitochondrial
dysfunction in the pathogenesis of PD (Moore et al., 2005).
Long-lasting intracellular calcium load results in mitochondrial
oxidative stress that can exacerbate neurodegeneration (Surmeier
and Schumacker, 2013). Consequently, the mitochondrial
production of adenosine tri-phosphate (ATP) drops rapidly and
a toxic calcium excess cannot be removed from the cell. This
cascade of pathological events is controlled by GABA activity
that may precisely dose the amount of calcium entering the
cell (Walker and Semyanov, 2007; Mosharov et al., 2009; Glass
et al., 2010). A decline in this calcium buffering capacity is
just responsible for neuronal loss in the substantia nigra in PD
(Hurley et al., 2013; Surmeier and Schumacker, 2013).
There is also another potent mechanism that controls
calcium-mediated processes within the CNS, and which,
when fails may initiate of neurodegeneration. The release
of neurotransmitters within neuronal networks activates
neighboring astrocytes that in turn, via GABA, inhibit the
further influx of calcium ions into the presynaptic neurons
(negative feedback in Figure 1). Astro-neuronal networks are
self-regulating systems (Rial et al., 2016). Excessive neuronal
activity is firstly tuned by increased GABA inhibition and, if
not successful, the density of GABA synaptical receptors and
the number of calcium channels are reduced (Petroff, 2002;
Moore et al., 2005; Surmeier and Schumacker, 2013). When
these mechanisms fail, the excitability of the neuronal network is
adjusted in the process of excitotoxicity that eliminates neurons
with excessive activity. When a neurotransmitter concentration
around the synaptic cleft cannot be decreased or reaches a higher
level (e.g., due to neuronal overexcitation) the neuron kills itself
by a process of apoptosis.
As a general role, GABA interneurons act as homeostatic
regulators of synaptic inhibition within principal cell networks.
GABA is released into the extracellular space and is then
transported into neurons and glial cells (Hawkins and Davis,
2005; Allaman et al., 2011). If the ambient GABA concentration
decreases, the neurons become more excitable (Walker and
Semyanov, 2007). Generally, the efficiency of GABA mediated
mechanisms depends on its concentration within the nervous
system. The concentration depends on the amount of GABA that
is synthesized and released, as well as on the activity of enzymes
and cofactors involved in its processing. In addition to GABA
release, there is also GABA uptake, the efficiency of which varies
from brain region to brain region and evenwithin specific regions
(Richerson and Wu, 2003). The astrocytes, besides regulating
neurotransmitter levels, also support the metabolism of neurons
(Allaman et al., 2011; Rial et al., 2016). For instance, they release
Frontiers in Neuroscience | www.frontiersin.org 4 June 2016 | Volume 10 | Article 269
Błaszczyk Neurodegeneration: GABA-Collapse Hypothesis
FIGURE 1 | A schematic illustration of neuro-glial interactions during synaptic transmission from a functional perspective of GABAergic system. All
brain structures, although anatomically and physiologically diverse, share a common mechanism that controls their activity and metabolism. The control is maintained
through a complex interaction between gamma-aminobutyric acid (GABA) and calcium (Ca2+) dependent neurotransmission and cellular metabolic functions.
Activation of both classical GABAA and GABAB receptors (GABAR) results in a hyperpolarization of neurons and play a critical role in long-term inhibition of synaptic
transmission. The α-SNCA plays an important role in these interactions by maintaining a supply/release of synaptic vesicles and the mitochondrial metabolic function
in a calcium-dependent manner. Generally, Ca2+/GABA mechanism stabilizes neuronal activity both at cellular and systemic levels. The collapse of this mechanism
may be decisive in the initiation and running of brain aging and neurodegeneration due to “triple hit” (too much calcium plus a build-up of α-SNCA and excitotoxicity).
Collapse of the GABA inhibition results in vasodilation which may change permeability the blood-brain barrier and may initiate inflammation of blood vessels and brain
tissue thus intensifying neurodegenerative processes in PD.
large amounts of lactate in the extracellular space that can diffuse
through the astrocytic network and rescue neuronal activity
during glucose deprivation.
A balance between excitation and inhibition ensures the
faultless functioning of neuronal and astro-neuronal networks
(Figure 1). To maintain the balanced activity of the brain the
glutamate-GABA-glutamate recycling process is used. Astrocytes
uptake glutamate and synthetize GABA in a calcium-dependent
manner (Walker and Semyanov, 2007). In this process, the L-
glutamic acid decarboxylase (GAD) and vitamin B6 as a cofactor
are used (Petroff, 2002). GAD exists in two isoforms: GAD65
and GAD67 that synthesize GABA at different locations in the
neurons, at different developmental times, and for functionally
different purposes (Pinal and Tobin, 1998). Only GAD65
synthesizes GABA for neurotransmission. After its Ca-inhibitory
action, GABA is recycled through the tricarboxylic acid cycle
back to glutamate. Recently, it became evident that defects of
these astrocytic functions and/or alterations of astrocyte–neuron
interaction, results in neuronal damage (Allaman et al., 2011).
This finding offers a promissing therapeutic strategy in PD. New
therapy consisting of insertion of the glutamic acid decarboxylase
gene into the subthalamic nucleus that results in partial but
significant relief of symptoms of Parkinson’s disease (LeWitt
et al., 2011).
CA2+/GABA AND PD MOTOR SYMPTOMS
The only output of the nervous system is the motor system,
whether in cognition or action (Grillner et al., 2005). It is also
reasonable to hypothesize that PD motor symptoms are mainly
due to basal ganglia deficiency (Błaszczyk, 1998; Brooks, 1998;
Bergman and Deuschl, 2002; Błaszczyk et al., 2007; Cenci, 2007).
The basal ganglia play an essential role in adaptive motor control
by allowing relevant motor programs to be executed while
inhibiting potentially competing movements (Grillner et al.,
2005; Cenci, 2007). In this control, the pallidal output keeps
the different sensori-motor and motivational centers (including
thalamus, ventral tegmental area, and substantia nigra) and their
target neurons under tonic (90 Hz) GABA inhibition (Grillner
et al., 2005). This unique spontaneously active GABA output may
be particularly vulnerable to aging and neurodegeneration. A
decline in the tonic GABA inhibitory activity of the basal ganglia
results in increasing co-activation of different competitive motor
programs (Cenci, 2007). This, in turn, causes co-activation of a
variety of muscle groups, including co-contractions of agonist
and antagonist muscles and progressive stiffness, which leads to
progressive changes in posture and a rigid gait (Błaszczyk et al.,
2007; Błaszczyk and Orawiec, 2011). GABA compounds that
cross the blood-brain barrier or increase GABA activity alleviate
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muscle stiffness caused by a lack of GABAergic tone. Also the use
of GABA-producing transplants for recovery of function in the
rat Parkinson model introduces a novel concept of therapeutic
intervention in Parkinson’s disease (Winkler et al., 1999).
Movement initiation and rapid transition between motor
programs at the level of basal ganglia are critically modulated
by a dopaminergic projection from the SNPC to the striatum.
The importance of this projection is illustrated by the dopamine-
dependent motor symptoms of PD (Cenci, 2007). Reduced
dopamine innervation of the striatum, as in PD, results in
hypokinesia and difficulty in initiating different motor programs.
Significantly, some of the cardinal PD motor symptoms:
postural instability, tremor, and freezing phenomenon do not
always improve with levodopa, and, in fact, can be made
worse.
An interesting feature of midbrain dopamine neurons and
the other brainstem nuclei that degenerate in Parkinson’s
disease is that they are autonomously active (pacemaker
activity), with prominent transmembrane calcium currents that
generate regular, slow, broad action potentials (2–4 Hz) in
the absence of synaptic input (Surmeier and Schumacker,
2013). Neurons in the substantia nigra pars compacta and the
subthalamic nucleus (STN) preferentially use CaV1.3 channels
for pacemaking which makes them more susceptible to calcium
mediated excitotoxicity and neurodegeneration. Thus, GABA
inhibition of Cav1.3 channel activity may be neuroprotective
for the remaining substantia nigra pars compacta neurons
in patients with Parkinson’s disease (Hurley et al., 2013).
Also fast-spiking neurons of the STN, that constitute the
"central pacemaker of the basal ganglia,” became targets for
transplants of protective GABA releasing cells (Winkler et al.,
1999; LeWitt et al., 2011). In both cases, the tight interaction
of neuro-glial units seems to be the main, if not the only,
protective mechanism against damage. Recently, the protective
effects of glial cell-derived neurotrophic factor (GDNF) for
midbrain dopaminergic neurons have been also reported
(Eserian, 2013; Ibáñez and Andressoo, 2016). Interestingly, the
neuroprotective effects were observed only when the GDNF
was delivered into the gabaergic striatum, but not directly
to the SNPC dopaminergic neurons (Ibáñez and Andressoo,
2016). This finding strengthens the proposed GABA- collapse
hypothesis.
The input GABA neurons of the basal ganglia have a high
threshold for activation and are essentially silent (Grillner et al.,
2005). An increasing threshold of striatal input due to GABA
deficiency would be manifested in bradykinesia and hypokinesia.
In this case, GABA deficiency at the striatal input to the basal
ganglia would require increased dopamine input. GABA striatal
spiny neurons forming an input system to the basal ganglia are
only activated during motor activity and they do not seem to
degenerate (Cenci, 2007).
Parkinsonian akinesia has been attributed to an imbalance
between movement-suppressing and movement-promoting
pathways within the basal ganglia (Cenci, 2007). In fact, all the
motor symptoms of PD may be explained solely by malfunctions
in the spinal and supra-segmental inhibitory networks that
utilize GABA (Figure 1).
GABA AND BLOOD-BRAIN BARRIER
Brain activity depends also on the balance between neuronal
activity and its metabolic demands. Neurodegeneration and
PD pathology may depend on brain metabolism (Figure 1).
Given the dynamic nature of brain activity and the considerable
metabolic needs of bioelectrically active nervous tissue, the
microcirculation of the brain must be highly responsive to
the tissue it supplies. Anatomical evidence confirmed a direct
innervation of the microvascular endothelium by GABAergic
neurons (Vaucher et al., 2000). GABA activity allows the
maintenance and optimization of metabolic, neurotrophic and
energetic supply of the brain by controlling neurovascular units
(Hawkins and Davis, 2005). This neuronal function depends also
on the Ca2+/GABA mechanisms. A normal level of GABA helps
maintain tightness and selectivity of the blood-brain barrier.
While the exact cause of chronic neurodegeneration of
PD is not known, increasing evidence suggests that chronic
inflammation is the fundamental process mediating the
progressive nature of the neurodegeneration characteristic of PD
(Glass et al., 2010). Induced by GABA deficit, inflammation may
amplify the pathology. Collapse of GABA inhibition results in the
relaxation of smooth muscle within the brain vessels. Long-term,
this may change the permeability of the blood brain barrier
(BBB) and thus may initiate inflammation of blood vessels and
brain tissue thereby intensifying neurodegenerative processes.
Damaged or poorly functioning BBB is more susceptible to
inflammatory responses involving microglia and astrocytes that
may contribute to PD progression (Glass et al., 2010). Many
environmental factors may influence inflammatory responses
that contribute to neurodegenerative pathologies, including
traumatic injury, systemic infection, diet and prolonged
occupational exposure to metals (Migliore and Coppedè, 2009;
Kwakye et al., 2015). Anatomical evidence has been found for
direct control of the neurovascular units and/or associated
astrocytic processes by excitatory neurotransmitters. The
Ca2+/GABA system plays a vital function here and its deficiency
can lead to the disruption of the BBB (Hawkins and Davis, 2005).
In conclusion, physiological control mechanisms within the
nervous system, and particularly the combined control of the
neuron’s activity and its metabolism, suggests that deficiency
in only one of these mechanisms may be responsible for the
progressive decline in brain function and neurodegeneration.
In this context, the GABA decline etiology appears to apply to
all human neurodegenerative processes initiated by abnormal
intracellular calcium levels. Linking such a vital mechanism of
synaptic transmission (and neuronal bioelectrical activity) with
metabolism (both at cellular and tissue level) by means of a
common reciprocal Ca2+/GABA inhibition results in a fragile
balance which is prone to destabilization and auto-destruction.
The process(es) is initiated in cells that are the weakest (less active
or overactive) within different brain regions. Then, depending on
genetic predisposition as well as hormonal and environmental
factors, the process can accelerate with rapidly progressing
degradation of the nervous system.
Decline in the Ca2+/GABA control initiates several cascading
processes leading to both weakened protective barriers (in
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particular, the blood-brain barrier) and accumulations of
intracellular deposits of calcium and the Lewy bodies. A future
and more complete therapeutic approach to PD should be aimed
firstly at slowing (or stopping) the progression of Ca2+/GABA
functional decline and thus slowing the aging/degeneration
processes within the nervous system. In this context, to
implement screening for early PD, it will be important to
develop a more precise understanding of the time-course of
the emergence of prodromal features of PD and the timing
of the onset of GABA threshold impairment that leads to
a progressive and irreversible neurodegradation and calcium-
dependent apoptosis. In conclusion, the original description
of PD as due to the selective damage of dopaminergic
neurons in the mesencephalon should be up-dated into
the concept of a severe multisystemic neurodegenerative
disorder of the brain, whose clinical symptoms reflect the
localization and progression of the most advanced GABA
pathology.
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